Method for producing product

By controlling the perfusion ratio and gene expression ratios in perfusion culture, the method addresses the challenge of maintaining stable cell density and productivity, achieving high-quality and high-productivity antibody production over time.

WO2024248120A1PCT designated stage expired Publication Date: 2024-12-05FUJIFILM CORP
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/019990
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

In perfusion culture, maintaining stable cell density and productivity over a long period is challenging due to reduced cell proliferation and quality issues, leading to reduced antibody quality and productivity.

Method used

Control the perfusion ratio (P/V) and the ratio of isovaleryl-CoA dehydrogenase gene (Ivd) to glycerol-3-phosphate dehydrogenase gene (Gpdh) expression levels within specific ranges to maintain cell proliferation and viable cell density, while adjusting isovaleric acid concentration and perfusion culture duration to optimize antibody production.

Benefits of technology

This approach allows for sustained high-quality product production with stable cell density and increased productivity over an extended period, reducing costs and medium usage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure 00000031_0000
    Figure 00000031_0000
Patent Text Reader

Abstract

The present invention addresses the problem of providing a method which is for producing a product by means of cell culture and by which the proliferative properties of cells are maintained and a high-quality product is obtained with high productivity over a long period of time. The present invention provides a method for producing a product, the method comprising performing perfusion culture of cells in a culture solution, wherein the perfusion ratio P (vvd) in the perfusion culture, the cell density V (×106 cells / ml) in the culture solution, and X, which is the ratio of the expression level of isovaleryl CoA dehydrogenase gene Ivd to the expression level of glycerol-3-phosphate dehydrogenase gene Gpdh in the culture solution, satisfy 1.0×10-5≤X×(P / V)≤1.0×10-4.
Need to check novelty before this filing date? Find Prior Art

Description

How the product is produced

[0001] The present invention relates to a method for producing a product, which comprises perfusion culturing cells in a culture medium.

[0002] Cell culture is carried out for the purpose of increasing the number of cells with useful properties, causing cells to produce products, etc. In the production of biopharmaceuticals such as antibodies, perfusion culture is often used to improve antibody productivity, in which the culture medium is continuously filtered and discharged while fresh medium containing nutrients is continuously supplied to the culture vessel.

[0003] For example, Patent Document 1 describes a method for producing a bispecific antibody product, comprising the steps of: (i) providing at least one mammalian cell capable of expressing a bispecific antibody product in a perfusion bioreactor; (ii) growing the mammalian cell culture at a first perfusion rate until a set viable cell density is reached; and (iii) maintaining the perfusion culture at a second perfusion rate, wherein the bispecific antibody product concentration in the bioreactor is maintained below a threshold value.

[0004] Patent Document 2 describes the production of a target protein by culturing animal cells that have a gene encoding the target protein and a foreign gene encoding isovaleryl-CoA dehydrogenase, and in which isovaleryl-CoA dehydrogenase is overexpressed.

[0005] JP 2021-505182 A International Publication No. WO2019 / 117136

[0006] Perfusion culture has attracted attention as a production method for improving the productivity of antibody pharmaceuticals. In perfusion culture, maintaining a roughly constant cell density during culture is important to obtain antibodies of stable quality over the long term. However, there are problems with cell proliferation during culture, such as an inability to maintain cell density and cell death during the culture process, resulting in a decrease in antibody quality and a decrease in productivity. The problem to be solved by the present invention is to provide a method for producing a product by cell culture that maintains cell proliferation and allows for the production of high-quality products with high productivity over the long term.

[0007] As a result of intensive research to solve the above problems, the present inventors discovered that, in perfusion culture, growth can be maintained and high-quality products can be obtained with high productivity over a long period of time by controlling the expression level of the isovaleryl-CoA dehydrogenase gene (Ivd) per cell, the cell density during culture, and the perfusion ratio so that a specific relationship is satisfied, thereby completing the present invention.

[0008] That is, the present invention provides the following inventions. <1> A method for producing a product, comprising perfusion culturing cells in a culture medium, wherein a perfusion ratio P(vvd) in the perfusion culture and a cell density V(×10 6 cells / ml), and X, which is the ratio of the expression level of the isovaleryl-CoA dehydrogenase gene Ivd to the expression level of the glycerol-3-phosphate dehydrogenase gene Gpdh in the culture medium, is 1.0 × 10 ―5 ≦X×(P / V)≦1.0×10 ―4 <2> A method for producing a product according to <1>, wherein the isovaleric acid concentration in the culture medium is 10 μmol / L or more and 1000 μmol / L or less. <3> A method for producing a product according to <1> or <2>, wherein X is 0.0010 or more and 0.0100 or less. <4> A method for producing a product according to any one of <1> to <3>, wherein the perfusion culture, after reaching a target viable cell density in the culture, comprises producing the product for a certain period of time while maintaining the viable cell density substantially constant. <5> The viable cell density that is maintained substantially constant is 30×10 6 cells / ml or more 400×10 6<6> A method for producing the product according to <4>, wherein the perfusion ratio is 0.3 to 5.0 during the period in which the viable cell density is maintained substantially constant. <7> A method for producing the product according to any one of <4> to <6>, wherein cell bleeding is performed by discharging the cell-containing culture medium to the outside of the system and adding medium in order to maintain the viable cell density substantially constant. <8> A method for producing the product according to <7>, wherein the cell bleed ratio in the cell bleed is 0.10 to 0.80 vvd. <9> A method for producing the product according to any one of <1> to <8>, wherein the perfusion culture period is 14 days to 200 days. <10> A method for producing the product according to any one of <1> to <9>, wherein the isovaleryl-CoA dehydrogenase gene Ivd is an endogenous gene. <11> A method for producing the product according to any one of <1> to <10>, wherein the cell is a CHO cell. <12> A method for producing the product according to any one of <1> to <11>, wherein the product is a protein. <13> A method for producing the product according to <12>, wherein the protein is an antibody. <14> A method for producing a product, comprising: a screening step of selecting cells in which the ratio of the expression level of the isovaleryl-CoA dehydrogenase gene Ivd to the expression level of the glycerol-3-phosphate dehydrogenase gene Gpdh is between 0.0010 and 0.0100; and a step of culturing the cells selected in the screening step, wherein the expression of the isovaleryl-CoA dehydrogenase gene Ivd in the cells is endogenous gene expression.

[0009] According to the method for producing a product of the present invention, cell proliferation can be maintained and high-quality products can be obtained with high productivity over a long period of time.

[0010] FIG. 1 shows a cell culture device.

[0011] The present invention will be described in detail below. In this specification, a numerical range indicated using "to" means a range that includes the numerical values ​​before and after "to" as the minimum and maximum values, respectively.

[0012] The method for producing a product of the present invention comprises perfusion culturing cells in a culture medium, and the method comprises: determining a perfusion ratio P(vvd) in the perfusion culture and a cell density V(×10 6 cells / ml), and X, which is the ratio of the expression level of the isovaleryl-CoA dehydrogenase gene Ivd to the expression level of the glycerol-3-phosphate dehydrogenase gene Gpdh in the culture medium, is 1.0 × 10 ―5 ≦X×(P / V)≦1.0×10 ―4 This is a way to satisfy the above.

[0013] The method for producing a product of the present invention can be suitably used as a method for producing a product by cell culture used in biopharmaceuticals, regenerative medicine, etc.

[0014] The culture medium contains both cells and culture supernatant. The cell density in the culture medium is V (×10 6 The viability (cells / ml) can be measured using a Vi-CELL XR viability cell analyzer manufactured by Beckman Coulter.

[0015] X, which is the ratio of the expression level of the isovaleryl-CoA dehydrogenase gene Ivd to the expression level of the glycerol-3-phosphate dehydrogenase gene Gpdh in the culture medium, can be determined by measuring the expression levels of Gpdh and Ivd, respectively, by real-time PCR (polymerase chain reaction). Specifically, reverse transcription is performed using total RNA recovered from cells in the culture medium. Real-time PCR (polymerase chain reaction) is performed using a primer homologous to endogenous Ivd and a primer for the glycerol-3-phosphate dehydrogenase Gpdh gene, and the expression level of the Ivd gene can be confirmed using the Gpdh gene for standardization.

[0016] The perfusion ratio P (vvd) and the cell density V (×10 6 cells / ml) and the expression level ratio, X, is 1.0 × 10 ―5 ≦X×(P / V)≦1.0×10 ―4 It would be fine if it was 2.0 x 10 ―5≦X×(P / V)≦8.0×10 ―5 Preferably, it is 3.0 × 10 ―5 ≦X×(P / V)≦5.0×10 ―5 is more preferred.

[0017] X x (P / V) = 1.0 x 10 ―5 By adjusting the concentration of isovaleric acid to 1.0×10 or more, an increase in the concentration of isovaleric acid can be suppressed and cell proliferation during culture can be appropriately maintained. ―4 By doing the following, the amount of medium used to remove isovaleric acid can be reduced, thereby reducing costs.

[0018] The concentration of isovaleric acid in the culture medium is preferably 10 μmol / L to 1000 μmol / L, more preferably 50 μmol / L to 800 μmol / L, and even more preferably 100 μmol / L to 500 μmol / L.

[0019] The concentration of isovaleric acid in the culture medium can be measured by withdrawing the culture medium from the culture tank, filtering the cells, and then subjecting the filtrate to chromatographic separation.

[0020] By setting the isovaleric acid concentration in the culture medium to 10 μmol / L or more, the amount of medium used for removing isovaleric acid can be reduced, thereby reducing costs.By setting the isovaleric acid concentration in the culture medium to 1000 μmol / L or less, cell growth during culture can be maintained appropriately.

[0021] X is preferably 0.0010 or more and 0.0100 or less, more preferably 0.0014 or more and 0.0080 or less, and even more preferably 0.0020 or more and 0.0050 or less. The lower limit of X is preferably 0.0014, more preferably 0.0020, and even more preferably 0.0025.

[0022] When X is 0.0010 or more, an increase in the isovaleric acid concentration can be suppressed, and cell growth during culture can be appropriately maintained.When X is 0.0100 or less, this can be achieved by endogenous gene expression, eliminating the need to introduce an exogenous gene for Ivd expression and reducing costs.

[0023] In the present invention, the cell culture method is perfusion culture. Perfusion culture is a culture method in which fresh medium is added and spent medium is simultaneously removed. Perfusion culture generally allows for a high viable cell density to be achieved. A typical perfusion culture begins with a batch culture start-up lasting one or two days, after which fresh feed medium is continuously, stepwise, and / or intermittently added to the culture, and spent medium is simultaneously removed. In perfusion culture, spent medium can be removed while maintaining viable cell density using methods such as sedimentation, centrifugation, or filtration. An advantage of perfusion culture is that the culture in which the target protein is produced can be maintained for a longer period of time than batch or fed-batch culture.

[0024] Perfusion can be continuous, stepwise, intermittent, or a combination thereof, preferably continuous. The animal cells are maintained in culture, and the removed spent medium may be substantially cell-free or contain far fewer cells than the culture. The product expressed by the cell culture can be maintained in culture or recovered by selecting the membrane pore size.

[0025] The period of perfusion culture is preferably 5 to 300 days, more preferably 14 to 200 days, even more preferably 14 to 100 days, and even more preferably 20 to 90 days. A culture period of 5 days or more is preferred because it increases the number of cells obtained and, if the cells produce a product, increases the amount of product produced. A culture period of 300 days or less is preferred from the viewpoint of preventing clogging of the filtration membrane used in perfusion culture and preventing contamination.

[0026] The perfusion ratio is not particularly limited, but is preferably 0.3 vvd or more and 5.0 vvd or less, more preferably 0.5 vvd or more and 3.0 vvd or less, and even more preferably 0.8 vvd or more and 2.0 vvd or less.

[0027] By setting the perfusion ratio to 0.3 or higher, the increase in isovaleric acid concentration can be suppressed, allowing cell proliferation to be maintained appropriately during culture.By setting the perfusion ratio to 5.0 or lower, the amount of medium used can be reduced, thereby reducing costs.

[0028] The perfusion ratio (vvd) refers to the volume of culture medium extracted / volume of culture medium in the culture vessel / day. Note that the perfusion ratio here is a different parameter from the example of bleeding, "(iv) When the capacitance of the culture medium exceeds the target, operate the pump extracting the culture medium at a speed of 0.3 vvd to 3 vvd."

[0029] The culture medium is usually removed from the culture vessel using a pump, but other available liquid-transporting means may also be used. The culture medium removed from the culture vessel is then subjected to treatments such as product recovery and dead cell removal. After product recovery and dead cell removal, the culture medium removed from the culture vessel may be partially discarded or returned to the culture vessel. If a loss of medium occurs due to the above treatments, it can be compensated for by, for example, supplying fresh medium to the culture vessel.

[0030] Preferably, perfusion culture involves producing a product for a certain period of time while maintaining a substantially constant viable cell density after the target viable cell density is reached in the culture. "Maintaining a substantially constant viable cell density" means that the viable cell density is maintained within ±20%, preferably within ±10%, more preferably within ±5%, and even more preferably within ±3% of the target viable cell density.

[0031] The viable cell density, which remains substantially constant, is 30 x 10 6 cells / ml or more 400×10 6 It is preferable that the concentration is 30×10 6 cells / ml or more 300×10 6 More preferably, it is 80 x 10 cells / ml or less. 6 cells / ml or more 240×10 6 More preferably, it is 80 x 10 cells / ml or less. 6 cells / ml or more 200×10 6 More preferably, it is 80 x 10 cells / ml or less. 6 cells / ml or more 160×10 6More preferably, the concentration is 100×10 6 cells / ml or more 120×10 6 It is particularly preferable that the concentration is 10 cells / ml or less. 6 It is sometimes written as M instead.

[0032] The viable cell density was 30 x 10 6 By increasing the viable cell density to 400 x 10 cells / ml or more, antibody productivity can be increased. 6 By adjusting the concentration to 10 ...

[0033] Viable cell density can be measured using a commercially available measuring device such as Beckman Coulter's Cell Viability Analyzer Vi-cell XR. For example, the Vi-cell software Vi-cell XR2.04 can be used, and the measurement parameters can be set as follows: Min diameter: 6 μm, Max diameter: 50 μm. Cell brightness: 85% Cell sharpness: 100 Viable cell spot brightness: 75% Viable cell spot area: 5% Minimum circularity:0 Decluster degree:Medium

[0034] In the present invention, preferably, in order to maintain a substantially constant viable cell density, cell bleeding (also called bleeding) is carried out by discharging the culture medium containing the cells from the system and adding a medium.

[0035] The cell bleed ratio in the cell bleed is preferably 0.10 to 0.80 vvd, more preferably 0.15 to 0.60 vvd.

[0036] By setting the cell bleed rate to 0.10 vvd or higher, growth can be maintained appropriately and antibody quality can be stably maintained. By setting the cell bleed rate to 0.80 vvd or lower, the amount of medium used can be reduced, thereby reducing costs.

[0037] Bleeding can be performed by any method as long as the culture solution containing the cells can be removed from the culture vessel. For example, as shown in Figure 1, a pipe for discharging the culture solution can be inserted into the culture solution, and the culture solution can be discharged from the culture vessel through the pipe.

[0038] Preferably, the culture medium may be bled while measuring the capacitance of the culture medium in-line. In-line measurement refers to measuring some measurement value that indicates the state of the culture medium while cell culture is being performed. To measure the capacitance in-line, for example, as shown in FIG. 1, a capacitance sensor may be inserted into the culture medium, and the capacitance of the culture medium may be measured in-line during culture.

[0039] Preferably, the bleeding may be automatically controlled. Automatic control means that the start and stop of bleeding are automatically controlled based on some measured value indicating the state of the culture solution. For example, the start and stop of bleeding can be automatically controlled based on a measured value of the capacitance of the culture solution.

[0040] Preferably, bleeding may be performed so that the variation in the capacitance of the culture medium measured inline is ±20% or less of the average capacitance during the production period. The variation in the capacitance of the culture medium measured inline is more preferably ±15% or less of the average capacitance during the production period, even more preferably ±12% or less of the average capacitance during the production period, and particularly preferably ±8% or less of the average capacitance during the production period. The lower limit of the variation in the capacitance of the culture medium is not particularly limited, and it is sufficient if it is 0% or more, but considering daily fluctuations in cell growth, variation of 0.1% or more will actually occur.

[0041] An example of bleeding can be performed by the steps of: (i) setting a target capacitance; (ii) setting a weight control value for the culture vessel; (iii) measuring the capacitance of the culture solution at a period of 0.1 seconds or less; (iv) when the capacitance of the culture solution exceeds the target, operating a pump that extracts the culture solution at a speed of 0.3 vvd to 3 vvd (where vvd means volume of culture solution extracted / volume of culture solution / day); (v) automatically supplying medium to the culture vessel while measuring the mass of the culture solution so that the fluctuation in the liquid volume of the culture solution is within 10%; and (vi) stopping the pump that extracts the culture solution when the capacitance of the culture solution falls below the target by 0.01% or more.

[0042] An example of a cell culture device that can be used for culturing cells in the present invention is shown in Figure 1. In Figure 1, a culture vessel 10 is a vessel that contains a culture medium containing cells. Cells are cultured in the culture medium inside the culture vessel 10.

[0043] Oxygen and air are sent from the sparger air supply pipe 1 and introduced into the culture solution through a sparger 11 having a pore size of 20 μm. The dissolved oxygen concentration in the culture solution can be adjusted by the sparger 11. The sparger is not particularly limited, but for example, a sparger having an average pore size of 1 μm or more and 300 μm or less in the gas release section and releasing a gas containing 30% by volume or more of oxygen can be used.

[0044] Air and carbon dioxide are introduced from the air supply pipe 2 into the upper part of the culture solution inside the culture vessel. Culture medium is supplied to the culture vessel from the culture medium supply pipe 3. A culture medium supply pump 15 is provided on the culture medium supply pipe 3. The exhaust pipe 4 is a pipe for exhausting air, and an exhaust filter 5 is connected to its end. The sampling pipe 6 is a pipe for collecting (sampling) the culture solution. The bleeding pipe 7 is a pipe for extracting (bleeding) the culture solution. A capacitance sensor 8 is attached so as to come into contact with the culture solution in the culture vessel. A dissolved oxygen sensor 9 is attached so as to come into contact with the culture solution in the culture vessel.

[0045] A stirring member having a stirring blade 12 may be provided inside the culture vessel 10. By rotating the stirring blade 12, the culture solution inside the culture vessel 10 is stirred, maintaining the homogeneity of the culture solution. The stirring of the culture solution by the stirring blade 12 also stirs the bubbles released by the sparger. The position of the stirring member having the stirring blade, the size of the stirring blade, etc. are not particularly limited and may be designed depending on the cell type used, the amount of culture solution, the amount of oxygen supplied, the position, number, size, etc. of the sparger. Furthermore, in order to quickly stir the bubbles coming out of the sparger and prevent the bubbles from coalescing, it is preferable to position the stirring blade 12 close to the sparger. Figure 1 shows the presence of foam 19.

[0046] A perfusion device 13 is connected to the bottom of the culture vessel 10. The culture solution inside the culture vessel 10 passes through the perfusion device 13 (hollow fiber MF membrane), and the permeate containing the cell product is removed from the culture vessel 10 by a delivery pump 16. The flow of the permeate is indicated by arrows 14. The perfusion device 13 may be equipped with a pressure gauge 17 and a diaphragm pump 18.

[0047] In the present invention, the cell suspension removed from the culture vessel may be passed through a separation membrane to separate it into a cell-containing solution and a permeate. This operation can be performed using a perfusion device. In this operation, the cell suspension removed from the culture vessel is separated into a cell-containing solution having a higher cell density than the cell suspension and a permeate having a lower cell density than the cell suspension. The cell density can be measured using a Vi-CELL XR viable cell analyzer manufactured by Beckman Coulter.

[0048] The membrane separation process is preferably tangential filtration, more preferably alternating tangential flow (ATF) or tangential flow, and most preferably ATF. Filters that can be used for ATF include SuATF10-S02PES and F2 RF02PES manufactured by Repligen.

[0049] As a medium for cell culture, a medium that is commonly used for culturing animal cells can be used. For example, CD OptiCHO (ThermoFisher), Dulbecco's Modified Eagle's Medium (DMEM), Eagle's Minimum Essential Medium (MEM), RPMI-1640 medium, RPMI-1641 medium, F-12K medium, Ham's F12 medium, Iscove's Modified Dulbecco's Medium (IMDM), McCoy's 5A medium, Leibovitz's L-15 medium, and EX-CELL™ 300 series (JRH Biosciences), CHO-S-SFMII (Invitrogen), CHO-SF (Sigma-Aldrich), CD-CHO (Invitrogen), IS CHO-V (Irvine Scientific), PF-ACF-CHO (Sigma-Aldrich), etc. may be used. Alternatively, a self-made medium may be used.

[0050] The medium may be supplemented with serum, such as fetal calf serum (FCS), or serum-free. The medium may be supplemented with additional components, such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements, plant protein hydrolysates, etc. Protein-free media may also be used.

[0051] The pH of the medium varies depending on the cells to be cultured, but is generally pH 6.0 to 8.0, preferably pH 6.4 to 7.6, and more preferably pH 6.7 to 7.4. The culture temperature is generally 30°C to 40°C, preferably 32°C to 39°C, and more preferably 36°C to 38°C, and the culture temperature may be changed during culture. The culture is carried out under CO 2 The process can be carried out in an atmosphere having a concentration of 0 to 40% by volume, preferably 2 to 25% by volume, and more preferably 3 to 20% by volume.

[0052] The amount of culture medium is preferably 1 L or more, more preferably 50 L or more, more preferably 100 L or more, and even more preferably 200 L or more.

[0053] The culture period is not particularly limited, but is generally from 5 days to 300 days, preferably from 14 days to 200 days, more preferably from 14 days to 100 days, and even more preferably from 20 days to 90 days. In the present invention, the culture period is preferably 14 days or more.

[0054] During the culture, the medium can be replaced, aerated, or stirred as necessary. When stirring is performed during the culture, the stirring speed is not particularly limited, but the stirring power per unit volume is generally 10 to 300 kW / m 3 and preferably 20 to 200 kW / m 3 and more preferably 30 to 100 kW / m 3 is.

[0055] The dissolved oxygen concentration in the culture solution can be set appropriately and is not particularly limited, but is generally 20 to 150%, preferably 30 to 120%, and more preferably 50 to 100%, when the saturated dissolved oxygen concentration in air at 1 atmosphere at 37°C is taken as 100%.

[0056] Cell culture can be carried out using a cell culture device having the configuration described above in this specification. The cell culture device may be any of a fermenter-type tank culture device, an airlift-type culture device, a culture flask-type culture device, a spinner flask-type culture device, a microcarrier-type culture device, a fluidized bed-type culture device, a hollow fiber-type culture device, a roller bottle-type culture device, or a packed tank-type culture device. From the viewpoint of homogenizing the culture environment, the culture vessel is preferably a single-use culture tank. From the viewpoint of homogenizing the culture environment, the cell culture device may also be a single-use culture tank.

[0057] The viscosity of the culture medium is preferably 1.2 mPa·s or more and less than 15 mPa·s, more preferably 1.4 mPa·s or more and less than 12 mPa·s, and particularly preferably 1.6 mPa·s or more and less than 10 mPa·s.

[0058] In the present invention, a pH adjuster may be added during the culture. In view of clogging of the filtration channel, the amount of pH adjuster added to the culture tank per day is preferably 8 mmol / day / L or less, more preferably 7 mmol / day / L or less. However, it is not necessary to add a pH adjuster. The pH adjuster is not particularly limited, but examples thereof include Na 2 CO 3 aqueous solution, aqueous NaOH or NaHCO 3 An aqueous solution is preferred, more preferably NaHCO 3 The pH adjuster may be added alone or mixed with the medium or antifoaming agent. To avoid local pH fluctuations in the culture solution due to the addition of the pH adjuster, it is preferable to add the pH adjuster to the medium.

[0059] The cells used in the present invention have the isovaleryl-CoA dehydrogenase gene Ivd, and the isovaleryl-CoA dehydrogenase gene Ivd is preferably an endogenous gene. An endogenous gene means a gene that a cell originally has, and is distinguished from an exogenous gene introduced from outside.

[0060] Furthermore, the present invention provides a method for producing a product, comprising: a screening step of selecting cells in which the ratio of the expression level of the isovaleryl-CoA dehydrogenase gene Ivd to the expression level of the glycerol-3-phosphate dehydrogenase gene Gpdh is 0.0010 or more and 0.0100 or less; and a step of culturing the cells selected in the screening step, wherein the expression of the isovaleryl-CoA dehydrogenase gene Ivd in the cells is endogenous gene expression.

[0061] The type of cell used in the present invention is not particularly limited, and examples include animal cells, plant cells, eukaryotic cells such as yeast, prokaryotic cells such as Bacillus subtilis, and Escherichia coli. The cells are preferably animal cells (more preferably mammalian cells) or insect cells, and most preferably mammalian cells. The cells may be primary cells or established cell lines.

[0062] Examples of cells include Chinese hamster ovary (CHO) cells, HEK cells (human embryonic kidney-derived cells), BHK cells, 293 cells, C127 cells, myeloma cells (such as NS0 cells), PerC6 cells, SP2 / 0 cells, hybridoma cells, COS cells (African green monkey kidney-derived cells), 3T3 cells, HeLa cells, Vero cells (African green monkey kidney epithelial cells), MDCK cells (canine kidney tubular epithelial cells), PC12 cells, and WI38 cells. The cells may also be stem cells such as embryonic stem cells (ES cells) or induced pluripotent stem cells (iPS cells). Among these, CHO cells, HEK cells, BHK cells, and hybridoma cells are preferred, CHO cells and HEK cells are more preferred, and CHO cells are most preferred. CHO cells are widely used for the production of recombinant proteins, such as cytokines, coagulation factors, and antibodies. It is preferable to use dihydrofolate reductase (DHFR)-deficient CHO cells, and for example, CHO-DG44 can be used as the DHFR-deficient CHO cells.

[0063] The higher the cell viability, the better, with 80% or more being preferred, 85% or more being more preferred, 90% or more being particularly preferred, and 95% or more being most preferred.

[0064] These cells may be cells into which a foreign gene encoding a protein to be expressed (e.g., an antibody) has been introduced. Preferably, the cells are antibody-producing cells. An expression vector can be used to introduce a foreign gene encoding a protein to be expressed into a cell. By introducing an expression vector containing DNA encoding the protein to be expressed, an expression regulatory sequence (e.g., an enhancer, a promoter, a terminator, etc.), and optionally a selection marker gene into a cell, a cell into which a foreign gene encoding the protein to be expressed has been introduced can be produced. There are no particular limitations on the expression vector, and it can be selected and used appropriately depending on the type of cell, purpose, etc.

[0065] Any promoter can be used as long as it is functional in mammalian cells. Examples include the promoter of the cytomegalovirus (CMV) IE (immediate early) gene, the SV40 early promoter, retrovirus promoters, metallothionein promoters, heat shock promoters, SRα promoters, and promoters and enhancers of Moloney murine leukemia virus. Furthermore, an enhancer of the human CMV IE gene may also be used together with the promoter.

[0066] Examples of selectable marker genes that can be used include drug resistance genes (neomycin resistance gene, DHFR gene, puromycin resistance gene, blasticidin resistance gene, hygromycin resistance gene, cycloheximide resistance gene), and fluorescent genes (genes encoding green fluorescent protein (GFP) or the like).

[0067] The method for introducing an expression vector into cells is not particularly limited, and for example, the calcium phosphate method, electroporation, liposome method, gene gun method, lipofection method, etc. can be used.

[0068] The method for producing a product according to the present invention comprises culturing cells using a cell culture device and producing a product from the cells. The present invention also provides a product produced by the method for producing a product according to the present invention.

[0069] In the present invention, the type of product is not particularly limited, but is preferably a protein. Examples of the product include recombinant polypeptide chains, recombinant secreted polypeptide chains, antigen-binding proteins, antibodies (e.g., human antibodies, humanized antibodies, chimeric antibodies, mouse antibodies, bispecific antibodies, etc.), Fc fusion proteins, fragmented immune immunoglobulins, single-chain antibodies (scFv), etc. In addition, the product may be an adenovirus, an adeno-associated virus, a lentivirus, etc.

[0070] The product is preferably an antibody, more preferably a human antibody, a humanized antibody, a chimeric antibody, or a mouse antibody. Examples of fragmented immune immunoglobulins include Fab, F(ab')2, and Fv. The class of the antibody is not particularly limited, and may be any class, such as IgG (e.g., IgG1, IgG2, IgG3, and IgG4), IgA, IgD, IgE, or IgM, although IgG and IgM are preferred for pharmaceutical use.

[0071] Human antibodies include all antibodies that have one or more variable and constant regions derived from human immunoglobulin sequences, hi one embodiment, all of the variable and constant domains are derived from human immunoglobulin sequences (fully human antibodies).

[0072] A humanized antibody has a sequence that differs from that of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and / or additions, such that the humanized antibody is less likely to provoke an immune response and / or provokes a less severe immune response when administered to a human subject compared to the non-human species antibody. In one example, certain amino acids within the framework and constant domains of the heavy and / or light chains of the non-human species antibody are mutated to produce a humanized antibody. In another example, constant domains from a human antibody are fused to variable domains of the non-human species.

[0073] A chimeric antibody is an antibody in which variable and constant regions of different origins are linked. For example, an antibody consisting of the heavy and light chain variable regions of a mouse antibody and the heavy and light chain constant regions of a human antibody is a mouse-human heterochimeric antibody. A recombinant vector that expresses a chimeric antibody can be produced by linking DNA encoding the variable region of a mouse antibody to DNA encoding the constant region of a human antibody and incorporating this into an expression vector. Recombinant cells transformed with the above vector are cultured to express the incorporated DNA, thereby obtaining the chimeric antibody produced during the culture.

[0074] Bispecific antibodies are antibodies that recognize two different antigen specificities. Various forms of bispecific antibodies exist. Reported methods for producing bispecific antibodies include linking two immunoglobulin molecules using crosslinkers such as N-succinimidyl 3-(2-pyridyldithiol) propionate or S-acetylmercaptosuccinic acid anhydride, or linking Fab fragments of immunoglobulin molecules. Bispecific antibodies can also be expressed by introducing genes encoding them into cells.

[0075] An Fc fusion protein refers to a protein having an Fc region, including antibodies. Fab is a monovalent fragment having the VL, VH, CL, and CH1 domains. F(ab')2 is a bivalent fragment having two Fab fragments linked by a disulfide bridge at the hinge region. An Fv fragment has the VL and VH domains of a single antibody arm. A single-chain antibody (scFv) is an antibody in which the VL and VH domains are joined via a linker (e.g., a synthetic sequence of amino acid residues) to form a continuous protein chain, where the linker is long enough to allow the protein chain to fold back on itself and form a monovalent antigen-binding site.

[0076] The antibody is not particularly limited, but examples thereof include an anti-IL-6 receptor antibody, an anti-IL-6 antibody, an anti-glypican-3 antibody, an anti-CD3 antibody, an anti-CD20 antibody, an anti-GPIIb / IIIa antibody, an anti-TNF antibody, an anti-CD25 antibody, an anti-EGFR antibody, an anti-Her2 / neu antibody, an anti-RSV antibody, an anti-CD33 antibody, an anti-CD52 antibody, an anti-IgE antibody, an anti-CD11a antibody, an anti-VEGF antibody, and an anti-VLA4 antibody.

[0077] The product may be recovered by simply recovering the culture medium, or by recovering the liquid from which at least a portion of the cells have been removed using, for example, a filter or a centrifuge, and any known method can be used without particular limitation. If it is desired to improve the purity of the product, change the solvent, or change the form, for example, to make it into a powder, the culture medium or the liquid can be subjected to further treatment.

[0078] It is also possible to collect a portion of the culture medium during perfusion, or to use a filter or centrifuge on a portion of the culture medium during perfusion, and collect the liquid from which at least a portion of the cells have been removed.

[0079] The product can be purified by a purification treatment. The obtained product can be purified to a high purity. Separation and purification of the product can be performed using separation and purification methods commonly used for proteins. For example, the product can be separated and purified by appropriately selecting and combining chromatography columns such as affinity chromatography, filters, ultrafiltration, salting out, dialysis, sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, isoelectric focusing, etc., but is not limited to these. The concentration of the product obtained above can be measured by absorbance measurement or enzyme-linked immunosorbent assay (ELISA), etc. Furthermore, when the product is an antibody, the antibody titer can also be measured using a commercially available analytical instrument such as Roche's Cedex Bio.

[0080] Examples of columns used in affinity chromatography include protein A columns and protein G columns. Chromatography other than affinity chromatography includes, for example, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography. These chromatographies can be performed using liquid phase chromatography such as HPLC (high performance liquid chromatography) or FPLC (fast protein liquid chromatography).

[0081] The product can be modified or partially depeptidized by treating it with an appropriate polypeptide-modifying enzyme before or after purification, such as trypsin, chymotrypsin, lysyl endopeptidase, protein kinase, or glucosidase.

[0082] The products produced by the present invention can be used in, for example, biopharmaceuticals and regenerative medicine.

[0083] The present invention will be explained in more detail with reference to the following examples, but the present invention is not limited to these examples.

[0084] <Establishment of antibody-producing cells> A vector containing a nucleic acid sequence encoding IgG1 was constructed, and the constructed vector was introduced into CHO-DG44 cells to generate CHO-DG44 cells expressing IgG1 (IgG1 cells). The prepared cells were screened, and three types of cells, CHO cell A, CHO cell B, and C, were used in the experiments. The CHO vector was constructed and introduced into the cells in accordance with Example 2 of JP-A-2016-517691. As described above, CHO cells producing monoclonal antibodies were prepared and used in the following experiments.

[0085] [Perfusion Culture Experiments] In the Examples and Comparative Examples, experiments were conducted using the cell culture apparatus shown in Figure 1. Antibody-producing CHO cells were grown to a target cell density by perfusion culture and cultured while maintaining that cell density. The culture period was continued for a total of 34 days, as long as the target cell density could be maintained without a decrease in cell proliferation. If cell proliferation decreased and the target cell density was not reached, or if a period of one day without cell bleeding continued after the target cell density was reached and the cell density could no longer be maintained, the culture was discontinued. Specific experiments were conducted as follows.

[0086] 1.3 L of medium was placed in a 3 L fermenter (Biostat (registered trademark) manufactured by Sartorius). The medium was prepared with reference to the replacement medium in Table 2 of JP-A-2000-517188. 0.5 × 10 6CHO cells were seeded at 100 cells / ml. The agitation speed was 160 rpm, and air was supplied from above at 38 ml / min and CO 2 2 ml / min from the bottom of the culture tank through a sparger installed in the culture tank so that the oxygen concentration in the culture solution was 80%. 2 was automatically controlled and supplied.

[0087] After culturing for 2 days after seeding, the cell culture medium was continuously supplied at a perfusion ratio of 0.6 vvd, and the recovered solution was collected by continuous filtration using ATF2 (manufactured by Repligen). On the 5th day, the perfusion ratio was changed to the predetermined ratio shown in Table 2 and maintained thereafter.

[0088] Thereafter, when the cell density reached the target cell density listed in Table 2, cell bleeding was performed while extracting a portion of the culture medium so as to maintain that cell density. Cell bleeding was performed automatically and continuously to maintain a constant cell density while monitoring the capacitance of the culture medium using a FUTURA sensor manufactured by ABER. The cells, medium, culture conditions, etc. used were changed as shown in the examples and comparative examples in Table 2, and multiple levels were tested. Thereafter, the culture was continued, and the evaluations described below were performed.

[0089] For 50 L cultivation, 50 L of medium was added to a Thermo Fisher Hypeforma 50 culture vessel, the agitation speed was set to 250 rpm, and the air flow rate from the top was set to 0.475 L / min + CO 2 The culture was carried out under the same conditions as the 1.3 L culture, except that the flow rate was 0.025 L / min and ATF4 manufactured by Repligen was used.

[0090] <Method for Automatic Cell Bleed Control> When cell bleeding was performed automatically, a FUTURA sensor manufactured by ABER was used to monitor the capacitance of the culture solution while automatically and continuously performing cell bleeding. Specifically, this was performed using the following method. (1) A target capacitance was set. (2) A weight control value for the culture tank was set. (3) The capacitance of the culture solution was measured at intervals of 0.1 s or less. (4) When the capacitance of the culture solution exceeded the target, the pump that extracts the culture solution was operated at a speed of 0.3 vvd to 3 vvd. (5) The culture medium was automatically supplied into the culture tank while measuring the weight of the culture tank so that the volume of the culture solution remained roughly constant. (6) When the capacitance of the culture solution fell 0.01% or more below the target, the pump that extracts the culture solution was stopped.

[0091] <Measurement and evaluation methods> (1) Measurement of cell density The culture medium was removed from the culture vessel and measured using a Beckman Coulter Cell Viability Analyzer Vi-cell XR. The Vi-cell software used was Vi-cell XR2.04, and the measurement parameters were set as follows: Min diameter: 6 μm Max diameter: 50 μm Dilution: cell density of 100 × 10 5 When the cell density was 100 x 10 cells / mL or less, the sample was not diluted and the measurement was performed at a dilution of 1. 5 For concentrations of 0.1 to 1.5 cells / mL, the sample was diluted 10 times and measured at a dilution of 10. Cell brightness: 85% Cell sharpness: 100 Viable cell spot brightness: 75% Viable cell spot area: 5% Minimum circularity: 0 Decluster degree: Medium

[0092] Measurement was carried out once a day using the above method.

[0093] (2) Measurement of antibody concentration in culture medium and permeate A sample of the culture medium was taken from the culture vessel, and the cells were filtered through Whatman (Pore Size 0.2 μm, 25 mm Diameter) manufactured by Cytiva. The filtrate was then measured using Cedex Bio manufactured by Roche. After sampling, the permeate was directly measured using Cedex Bio manufactured by Roche. Measurement was performed once a day using the above method.

[0094] (3) Measurement of Mannose 5 (M5) as an Antibody Quality Measurement of the N-glycan profile, including M5, was performed as follows. The antibody in the antibody recovery solution obtained was digested with peptide-N-glycosidase F to excise the N-glycans. The excised glycans were then fluorescently labeled with 2-aminopyridine, and mannose 5 was quantitatively analyzed by reverse-phase HPLC (high performance liquid chromatography), and the mannose 5 peak relative to the total peak area was calculated.

[0095] (4) Measurement of isovaleric acid concentration in culture solution A sample of the culture solution was taken from the culture tank, and the cells were filtered through Whatman (Pore Size 0.2 μm, 25 mm diameter) manufactured by Cytiva. The content of isovaleric acid in the filtrate was measured by chromatographic separation using ICS-2100 manufactured by DIONEX and an Ion Pac AS11-HC column.

[0096] (5) Measurement of the ratio X of the expression level of the isovaleryl-CoA dehydrogenase gene Ivd to the expression level of the glycerol-3-phosphate dehydrogenase gene Gpdh in the culture medium. Cells in the culture medium were treated with an RNeasy plus mini kit (Qiagen) to recover total RNA. The resulting total RNA was reverse transcribed using PrimeScript™ RT Master Mix (Perfect Real Time, Takara). Primers (SEQ ID NOS: 1 and 2) homologous to endogenous Ivd and primers (SEQ ID NOS: 3 and 4) for the glycerol-3-phosphate dehydrogenase Gpdh gene as an internal standard were designed, and real-time PCR (polymerase chain reaction) was performed using SYBR® Premix Ex Taq™ (Tli RNase H Plus, Takara). SEQ ID NOS: 1 to 4 are shown in Table 1. The expression level of the Ivd gene was confirmed using the Gpdh gene for standardization.

[0097]

[0098] <Evaluation> On the final day of culture, proliferation and mannose 5 (M5) antibody quality were evaluated and an overall evaluation was performed. Culture was discontinued if cell proliferation decreased and the target cell density was not reached, or if, after reaching the target cell density, no cell bleeding occurred for a day and the target cell density could no longer be maintained. Table 2 shows the measurement results on the final day of culture.

[0099] (1) Proliferation D: The target cell density was not reached, or the target cell density was reached but within 34 days after the start of culture, there was a period of one day where cell bleed did not occur, and 120M could not be maintained, so culture was discontinued. B: Culture was continued until the 34th day after the start of culture, and the cell bleed rate on the 34th day was less than 0.10 vvd. A: Culture was continued until the 34th day after the start of culture, and the cell bleed rate on the 34th day was 0.10 vvd or more.

[0100] (2) Mannose 5 (M5) as antibody quality C: Mannose 5 is 7% or more B: Mannose 5 is 4% or more but less than 7% A: Mannose 5 is less than 4%

[0101] (3) Overall evaluation D: If there is a D rating C: If there is no D rating and there is one or more C ratings B: If all ratings are B or higher and there is one or less A ratings A: If all ratings are B or higher and there are two A ratings

[0102] The measurement results for each example and each comparative example are shown in Table 2.

[0103] [Flask Batch Culture Experiment] To confirm that cells with high Ivd gene expression levels can be screened in advance by flask culture, batch culture in flasks was also carried out in parallel with the above-mentioned perfusion culture. The specific experiment was carried out as follows.

[0104] In a 125 mL flask, the same cells as those used in the perfusion culture were added at 0.5 × 10 6 The cells were seeded at a density of 1000 cells / ml to a volume of 30 ml, and incubated at 37°C, 5% CO 2 The culture was performed under a 500-kJ / s system with shaking at 140 rpm in a 1000 kJ / s atmosphere. Four days after inoculation, the culture medium was sampled, and the ratio X of the expression level of the isovaleryl-CoA dehydrogenase gene Ivd to the expression level of the glycerol-3-phosphate dehydrogenase gene Gpdh in the culture medium was measured according to the following procedure.

[0105] The cells in the culture medium were treated with an RNeasy plus mini kit (Qiagen) to collect total RNA. The resulting total RNA was reverse transcribed using PrimeScript™ RT Master Mix (Perfect Real Time, Takara). Primers (SEQ ID NOS: 1 and 2) homologous to endogenous Ivd and primers (SEQ ID NOS: 3 and 4) for the glycerol-3-phosphate dehydrogenase (Gpdh) gene as an internal standard were designed, and real-time PCR (polymerase chain reaction) was performed using SYBR® Premix Ex Taq™ (Tli RNaseH Plus, Takara). The Gpdh gene was used for standardization to confirm the expression level of the Ivd gene. The measurement results for each example and each comparative example are shown in Table 2.

[0106]

[0107] 1 Sparger air supply pipe 2 Air supply pipe 3 Culture medium supply pipe 4 Exhaust pipe 5 Exhaust filter 6 Sampling pipe 7 Bleeding pipe 8 Capacitance sensor 9 Dissolved oxygen sensor 10 Cultivation vessel 11 Sparger 12 Stirring blade 13 Perfusion device 14 Flow of permeate 15 Culture medium supply pump 16 Delivery pump 17 Pressure gauge 18 Diaphragm pump 19 Foam

Claims

1. A method for producing a product, comprising perfusion culturing cells in a culture medium, the method comprising: determining a perfusion ratio P(vvd) in the perfusion culture and a cell density V(×10 6 cells / ml), and X, which is the ratio of the expression level of the isovaleryl CoA dehydrogenase gene Ivd to the expression level of the glycerol-3-phosphate dehydrogenase gene Gpdh in the culture medium, is 1.0 × 10 ―5 ≦X×(P / V)≦1.0×10 ―4 A method for producing a product that satisfies the above requirements.

2. The method for producing the product according to claim 1, wherein the concentration of isovaleric acid in the culture medium is 10 μmol / L or more and 1000 μmol / L or less.

3. The method for producing the product according to claim 1, wherein X is 0.0010 or more and 0.0100 or less.

4. A method for producing a product according to any one of claims 1 to 3, wherein the perfusion culture comprises producing the product for a certain period of time after a target viable cell density is reached in the culture, while maintaining the viable cell density substantially constant.

5. The viable cell density remains substantially constant at 30×10 6 cells / ml or more 400×10 6 The method for producing the product according to claim 4, wherein the concentration of the product is less than 1000 cells / ml.

6. The method of producing the product according to claim 4, wherein the perfusion ratio is greater than or equal to 0.3 and less than or equal to 5.0 during the period during which the viable cell density is maintained substantially constant.

7. The method for producing the product according to claim 4, further comprising the step of performing cell bleeding by discharging the culture medium containing the cells from the system and adding medium in order to maintain the viable cell density substantially constant.

8. The method of claim 7, wherein the cell bleed ratio in the cell bleed is 0.10 to 0.80 vvd.

9. A method for producing the product described in any one of claims 1 to 3, wherein the period of the perfusion culture is from 14 days to 200 days.

10. A method for producing the product described in any one of claims 1 to 3, wherein the isovaleryl CoA dehydrogenase gene Ivd is an endogenous gene.

11. A method for producing the product according to any one of claims 1 to 3, wherein the cells are CHO cells.

12. A method for producing a product according to any one of claims 1 to 3, wherein the product is a protein.

13. The method of producing the product of claim 12, wherein the protein is an antibody.

14. A method for producing a product, comprising: a screening step of selecting cells in which the ratio of the expression level of the isovaleryl CoA dehydrogenase gene Ivd to the expression level of the glycerol-3-phosphate dehydrogenase gene Gpdh is 0.0010 or more and 0.0100 or less; and a step of culturing the cells selected in the screening step, wherein the expression of the isovaleryl CoA dehydrogenase gene Ivd in the cells is endogenous gene expression.

Citation Information

Patent Citations

  • Serum-free mammalian cell culture medium and uses thereof

    JP2000517188A

  • Method of expression

    JP2016517691A

  • Continuous manufacturing process for bispecific antibody products

    JP2021505182A

  • Tumor antigen protein and utilization thereof

    WO2004029248A1

  • Selective culture method and separation method for small hepatocytes with the use of hyaluronic acid

    WO2006001473A1